Haematology 2018

Immune-related adverse events

• Overall, grade 3 or 4 irAEs are observed in 7–12% of patients with solid tumors who receive single anti-PD-1 or anti-PD-L1 antibodies. • A predictable pattern of irAEs has been observed in such patients; dermatologic and gastrointestinal toxicities appear early, and hepatic toxicities or endocrinopathies are seen later • In patients with lymphoid neoplasms, irAEs of any grade appear in 72%- 100% of patients. • Common irAEs include thrombocytopenia, neutropenia, fatigue, infusion reaction, hypothyroidism, rash, diarrhea, nausea, pyrexia, pneumonitis, diarrhea, fatigue, back pain, decrease in platelets, dry skin, and cough.